

Contributions of GeneXpert® to TB diagnosis in Myanmar

Z. Burger,¹ H. T. Aung,² M. Seifert,¹ T. T. Mar,³ V. Harris,⁴ R. E. Colman,¹ T. C. Rodwell,¹ S. T. Aung³

¹University of California San Diego, La Jolla, CA, USA; ²Clinton Health Access Initiative, Yangon, ³Ministry of Health and Sports, Naypyitaw, Myanmar; ⁴Foundation for Innovative New Diagnostics, Geneva, Switzerland

SUMMARY

BACKGROUND: Xpert® MTB/RIF, a rapid, molecular TB diagnostic assay, can detect *Mycobacterium tuberculosis* and rifampin resistance directly from clinical sputum samples in <2 h with high sensitivity and specificity. The added diagnostic value of Xpert over smear microscopy at a national level in Myanmar has not been previously reported.

METHODS: We evaluated 339,358 Xpert and demographic records captured from January 2015 to December 2018 as part of the Myanmar National TB Program Data Utilization and Connectivity Project to examine the additional diagnostic yield of Xpert relative to smear for the detection of *M. tuberculosis* for TB diagnosis in

Myanmar, with a focus on people living with HIV (PLHIV) and sample type.

RESULTS: Use of Xpert increased TB case detection by 40% compared to smear microscopy results. Among PLHIV, use of Xpert increased TB case detection by almost 100% compared to smear microscopy results.

CONCLUSION: Xpert testing identified more patients with TB than smear microscopy alone, particularly in cohorts with significant proportions of PLHIV. The use of Xpert as a screening tool in countries with a high burden of TB could lead to significantly increased diagnosis of TB at a regional and national level.

KEY WORDS: tuberculosis; Xpert; Myanmar

Myanmar (population: over 54 million) ranks among the 30 highest TB burden countries as classified by the WHO and has one of the highest rates of TB-HIV coinfection in the world.¹ Myanmar has made significant progress in reducing new TB infections in recent years through a rigorous program of testing and treatment developed by the Myanmar National TB Programme (NTP), and recently met the WHO milestone of a 20% reduction in TB incidence as part of the End TB Strategy set in 2015.¹ The program is centered around a national network of Xpert® MTB/RIF instruments (Cepheid, Sunnyvale, CA, USA) used for the diagnosis of TB and detection of rifampin (RIF) resistant TB.

Xpert is a rapid nucleic-acid amplification test (NAAT) that has dramatically improved the detection and diagnosis of *Mycobacterium tuberculosis* globally. Xpert is recommended for both diagnosis of TB and identification of RIF resistance by the WHO,² but quantification of the diagnostic impact of implementing Xpert at a national level in Myanmar has not been previously reported.

Despite the improved performance of Xpert diagnosis over smear microscopy, smear microscopy remains the foundation of TB diagnosis in many low-

and middle-income countries due to its simplicity and low cost. However, smear microscopy has relatively low sensitivity (20–60%),^{3,4} especially in people living with HIV (PLHIV 9–39%),^{5–7} who have a lower bacillary load in their sputum samples compared with HIV-negative individuals.^{8,9} Due to Xpert's high sensitivity, its use among PLHIV has consistently increased the detection of TB in these populations.^{10–12}

Few large-scale studies of high-burden countries have assessed the added value of Xpert for bacterial confirmation of TB at a national scale.^{13,14} Our study objective was primarily to compare the diagnostic yield of Xpert with traditional smear microscopy for the detection of *M. tuberculosis* for TB diagnosis in Myanmar, with a focus on PLHIV. Additionally, given that Xpert can be used to test a variety of clinical sample types, our secondary objective was to examine Xpert results for the detection of *M. tuberculosis* in blood, cerebrospinal fluid (CSF), gastric lavage, and saliva.

METHODS

Study data

In our analysis, we used Xpert and demographic data captured from January 2015 to December 2018 as part of the Myanmar Data Utilization and Connec-

TCR and STA are co-senior authors.

Correspondence to: Timothy Rodwell, University of California San Diego, 9500 Gilman Dr, La Jolla, CA 92093, USA. email: trodwell@ucsd.edu

Article submitted 11 January 2022. Final version accepted 21 March 2022.

Table 1 Added value of Xpert based on HIV status

	HIV-positive			HIV-negative		
	Total* n (%)	Adult n (%)	Pediatric n (%)	Total* n (%)	Adult n (%)	Pediatric n (%)
Xpert MTB-positive	13,063	12,909	112	71,534	69,497	1,695
2015	2,559	2,539	17	6,007	5,882	111
2016	2,954	2,911	32	11,030	10,727	270
2017	3,540	3,497	32	23,398	22,639	597
2018	4,010	3,962	31	31,099	30,249	717
Xpert MTB-positive, smear-positive	6,560 (50.2)	6,479 (50.2)	58 (51.8)	55,165 (77.1)	53,660 (77.2)	1,235 (72.9)
2015	1,202 (47.0)	1,187 (46.8)	13 (76.5)	3,713 (61.8)	3,642 (61.9)	61 (55.0)
2016	1,537 (52.0)	1,519 (52.2)	12 (37.5)	7,913 (71.7)	7,710 (71.9)	183 (67.8)
2017	1,757 (49.6)	1,733 (49.6)	17 (53.1)	18,126 (77.5)	17,563 (77.6)	430 (72.0)
2018	2,064 (51.5)	2,040 (51.5)	16 (51.6)	25,413 (81.7)	24,745 (81.8)	561(78.2)

* Includes records without age recorded.

tivity Project. This project was developed by the Myanmar NTP with the assistance of FIND (Foundation for Innovative New Diagnostics, Geneva, Switzerland), and has been described previously in Seifert et al.¹⁵ Briefly, Xpert results from clinical sites distributed across the country were automatically generated by the instrument and collected centrally using the GxAlert connectivity solution from System-One (Northampton, MA, USA); associated demographic data were entered into an electronic data collection system at each clinical site. While the decision-making process for determining which individuals received Xpert testing evolved over the project period as part of the continued rollout of Xpert testing in Myanmar, the final inclusion criteria for Xpert testing were individuals who were at risk for TB (i.e., presumptive TB patients) and 1) individuals at risk of having drug-resistant TB; 2) individuals living with HIV; 3) individuals with diabetes; 4) persons with a history of TB treatment; and 5) children under 15 who were able to produce sputum. Individuals with positive TB smears at 2 or 5 months after treatment initiation were also referred for additional Xpert testing to detect potential RIF resistance during treatment. All samples were evaluated with direct smear microscopy using either fluorescence or Ziehl-Neelsen staining techniques, depending on site testing capacity.

Data were stripped of all unique patient identifiers prior to this analysis. The final dataset included Xpert test records from 87 clinical sites across Myanmar and included the following variables: test date, Xpert assay result (including both *M. tuberculosis* and RIF resistance detection), smear status, sex, age category, HIV status, and for a subset of patients, clinical sample type.

Analyses and statistics

The data presented here are based on standard-of-care data from the Myanmar NTP. The WHO considers Xpert to be a “reference” level test, with a pooled sensitivity and specificity of 85% and 98%,

respectively (sensitivity among smear- and culture-positive samples was 98%; this was 67% in smear-negative, culture-positive samples).^{16,17} Therefore, results that were positive on Xpert in this study were considered to be “true-positives” for our analyses.

We excluded any Xpert sample that did not have an accompanying positive or negative smear result. In our sub-analyses of Xpert and smear results by HIV status (Table 1), any sample that did not have an HIV status or age was excluded from that analysis. In Table 1, adults were defined as age ≥ 18 years, while the pediatric population was defined as age < 18 years. All analyses were performed using STATA/SE v16.1 (Stata Corp, College Station, TX, USA).

Ethics

This study received ethics approval from the Ethics Review Committee, Department of Medical Research, Ministry of Health and Sports, Naypyitaw, Republic of the Union of Myanmar (Approval number: Ethics/DMR/2018/155) for analysis of study data and was classified as exempt from review by the University of California San Diego Institutional Review Board, La Jolla, CA, USA.

RESULTS

A total of 339,358 Xpert results were collected from 2015 through 2018 by the Myanmar Data Utilization and Connectivity Project. Records without smear results were removed from the dataset ($n=9,095$). *M. tuberculosis* was detected in 141,021 samples (44.8%) using Xpert, with 158,699 (50.4%) *M. tuberculosis*-negative results and 15,093 (4.8%) results recorded as “Error,” “Invalid,” or “No Result.” Approximately 17% of the study population was HIV-positive, 41% HIV-negative, and 42% had unknown HIV status. Among the HIV-positive individuals, 23.9% were Xpert *M. tuberculosis*-positive, while 55.5% of the HIV-negative individuals and 43% of the HIV-unknown individuals were Xpert *M. tuberculosis*-positive. See Table 2.

Table 2 Characteristics of the study population stratified by HIV status

	HIV status		
	Positive (n = 54,732) n (%)	Negative (n = 128,931) n (%)	Unknown (n = 131,150) n (%)
Xpert result			
MTB-positive	13,063 (23.9)	71,534 (55.5)	56,424 (43.0)
Rifampicin-resistant	1,113 (8.5)	6,363 (8.9)	6,336 (11.2)
<i>M. tuberculosis</i> invalid/error/no result	3,024 (5.5)	5,730 (4.4)	6,339 (4.8)
Smear result			
Smear-positive	7,077 (12.9)	59,431 (46.1)	42,001 (32.0)
Smear-negative	47,655 (87.1)	69,500 (53.9)	89,149 (68.0)
Age, years, median [IQR] (n = 1,638 missing)	36 [30–44] (n = 147 missing)	45 [32–59] (n = 611 missing)	47 [32–60] (n = 880 missing)
Sex			
Female	17,900 (32.7)	42,447 (32.9)	46,759 (35.7)
Male	36,627 (66.9)	85,891 (66.6)	83,619 (63.8)
Unknown/missing	205 (0.4)	593 (0.5)	772 (0.6)
Test year (% by year)			
2015	9,739 (23.9)	11,552 (28.3)	19,473 (47.8)
2016	11,739 (19.4)	21,022 (34.7)	27,886 (46.0)
2017	15,507 (16.4)	40,143 (42.5)	38,817 (41.1)
2018	17,747 (14.9)	56,214 (47.3)	44,974 (37.8)

IQR = interquartile range.

The mean age of the individuals studied was 44.1 years (standard deviation 17.6, interquartile range 31–57). There was a statistically significant age difference between individuals recorded as HIV-positive, HIV-negative or HIV-unknown as determined using one-way analysis of variance ($P < 0.0001$). A Tukey post-hoc test revealed that HIV-positive individuals were significantly younger than individuals recorded as HIV-negative or -unknown ($P < 0.0001$).

The number of individuals tested using Xpert over time tripled from 40,764 in 2015 to 118,935 in 2018, as additional Xpert testing sites across Myanmar were continuously added to the project. Overall, the absolute number of HIV-positive individuals tested between 2015 and 2018 increased year over year. However, the proportion of HIV-positive individuals tested decreased from 2015 through 2018 (Table 2). The RIF prevalence reported in Table 2 reflects the RIF resistance detected within the study population rather than the prevalence of RIF resistance among all TB cases in Myanmar.

A total of 141,021 samples were Xpert *M. tuberculosis*-positive. Of these positive samples, 100,834 (71.5%) were smear-positive and 40,187 (28.5%) were smear-negative. Therefore, smear captured only 71.5% (100,834/141,021) of likely TB cases using Xpert as reference. Additionally, 4,277 (1.3%) samples were classified as smear-positive and *M. tuberculosis*-negative using Xpert. Xpert-negative, smear-positive patients underwent further evaluation, and those with abnormal radiographic findings were clinically diagnosed with TB and treated according to the NTP protocol. The added value of Xpert is even more pronounced among PLHIV. Smear captured only 50.2% (6,469/12,909)

of the total Xpert-positive cases among adults living with HIV (Table 1). Similarly, among HIV-positive children, smear captured only 51.8% (58/112) of TB cases detected using Xpert. Overall, using Xpert allowed healthcare workers to detect almost twice as many adults living with HIV and co-infected with *M. tuberculosis* than smear (12,909 vs. 6,479), and almost twice as many children living with HIV and TB than smear alone (112 vs. 58).

Xpert detection of *M. tuberculosis* was also higher than smear detection of *M. tuberculosis* among the HIV-negative populations. Smear captured only 77.2% of TB cases among HIV-negative adults and 72.9% of TB cases among HIV-negative children (Table 1). Overall, Xpert increased TB case detection by 40% compared to smear alone.

There were 21,730 samples labelled by sample type in our database and the vast majority (92.6%) were sputum samples. Other sample types collected included blood, gastric lavage, CSF, and saliva (Table 3). Xpert was used effectively to detect TB across a broad range of sample types, with only a very small percentage of samples documented to have indeterminate results (error, invalid, or no result) across all sample type categories. The added value of Xpert was highest among CSF and gastric lavage samples. Gastric lavage sampling was performed exclusively among children with an average age of 4 years. Four effusion samples and one pus sample were excluded from the analysis due to low sample size.

DISCUSSION

The overall goal of our study was to compare the diagnostic yield of Xpert to traditional smear microscopy for detection of *M. tuberculosis* for TB

Table 3 Details of Xpert-positives among diverse sample types

Sample type/total of sample type tested	Blood (n = 24) n (%)	CSF (n = 204) n (%)	Gastric lavage (n = 437) n (%)	Saliva (n = 911) n (%)
Xpert MTB-positive	13 (54.2)	13 (6.4)	19 (4.4)	237 (26.0)
Xpert indeterminate (error, invalid or no result)	0 (0.0)	5 (2.5)	4 (0.9)	30 (3.3)
Xpert MTB-positive, smear-positive, n (smear-positive/Xpert MTB-positive)	12 (92.3)	0 (0.0)	2 (10.5)	97 (40.9)

CSF = cerebrospinal fluid.

diagnosis in Myanmar. Over 28% of the almost 141,000 TB cases detected in Myanmar from 2015 through 2018 were smear-negative, but Xpert-positive. With Myanmar's steady incorporation of network-linked Xpert instruments across a growing number of clinical sites, 40% more cases of TB were diagnosed compared to what would have been diagnosed with traditional smear microscopy alone. The introduction of Xpert had an even more profound effect among PLHIV; almost 100% more TB cases among the total adult and pediatric HIV-positive populations were diagnosed using Xpert compared to traditional smear microscopy. These are cases that would have otherwise been missed if smear alone was used for the detection of TB in Myanmar (Table 1).

Our results support previous research that has shown that sputum smear microscopy is negative in more than half of patients with HIV-associated TB.^{8,10,18} This is critical at a programmatic level, as undetected and untreated TB disease is more likely to advance to disseminated disease in PLHIV.¹⁹ Xpert's superior diagnostic capability across a variety of different sample types has significant potential to decrease morbidity and mortality among these patients through earlier TB detection and treatment.^{4,17,20}

Of the 21,730 samples labelled by sample type in our database, the vast majority (92.6%) were sputum samples. Other sample types collected included blood, gastric lavage, CSF, and saliva (Table 3). The test indeterminate rate of Xpert across all sample types was low (<4%), suggesting that Xpert can be reliably used to detect *M. tuberculosis* across a diverse range of sample types when sputum is not available. The added value of Xpert in non-sputum sample types was highly variable, ranging from 8% in blood to 100% in CSF. These findings from the Myanmar NTP suggest that Xpert can be effectively used to great affect among pediatric populations (who often require gastric lavage as a clinical sample²¹), and PLHIV who can have higher rates of extrapulmonary TB disease requiring non-pulmonary samples for Xpert diagnosis. While we had no data on the reasons for different sample types being collected for each patient, we assumed based on NTP protocols, that alternative samples were collected only when sputum samples were not obtainable or when extrapulmo-

nary disease was indicated. Regardless of the reason for alternative sample collection, different sample sizes made it difficult to interpret the added value of Xpert by sample type.

There were several limitations to this study. The data were collected for programmatic purposes and were not collected under research conditions. The most important limitation this introduced was the lack of a common TB reference culture standard against which we could have estimated the comparative sensitivity and specificity of both Xpert and microscopy. To estimate the potential diagnostic advantage of Xpert vs. microscopy we had to assume Xpert-positive cases were "true-positives". While there is a possibility that a small fraction of these Xpert-positive results are "false-positives," it is unlikely to be significant, as Xpert is a WHO-endorsed TB reference standard and it has been well documented that Xpert is highly sensitive and specific for TB.¹⁷

Despite the limitations of this study, these data from the Myanmar NTP, which include almost 150,000 TB cases over 4 years, indicate that Xpert can have a substantial diagnostic advantage over acid-fast bacilli smear microscopy alone. With Xpert, the Myanmar NTP was able to capture 40% more TB cases in the general population and almost 100% more TB cases among PLHIV than if they had continued to rely on smear alone. There are, however, valid pragmatic arguments for the continued strengthening of microscopy networks globally due to concerns about the cost, sustainability and reach of molecular techniques at all levels of the healthcare system.²² We support this view that existing smear microscopy networks should not be abandoned but rather enhanced by the adoption of national testing network using linked molecular diagnostic tests, as countries that continue to use smear microscopy exclusively for the diagnosis of TB risk missing a substantial portion of their total TB cases. Incorporating Xpert testing in high TB burden countries, particularly if their populations have significant proportions of PLHIV, could lead to improved TB detection, earlier treatment initiation and lower mortality for patients.²³⁻²⁷

Acknowledgements

MS received support from National Institutes of Health/National

Heart, Lung, and Blood Institute, Bethesda, MD, USA (T32HL134632). Data collection was supported in part through a grant from the Bill and Melinda Gates Foundation, Seattle, WA, USA (OPP1148400).

Conflicts of interest: none declared.

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

- World Health Organization. Global tuberculosis report, 2021. Geneva, Switzerland: WHO, 2021.
- World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis-rapid diagnostics for tuberculosis detection: web annex 4: evidence synthesis and analysis. Geneva, Switzerland: WHO, 2021.
- Steingart KR, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. *Lancet Infect Dis* 2006;6(10):664–674.
- Lombardi G, et al. Diagnosis of smear-negative tuberculosis is greatly improved by Xpert MTB/RIF. *PLoS One*. 2017;12(4):e0176186.
- Ngabonziza JCS, et al. Diagnostic performance of smear microscopy and incremental yield of Xpert in detection of pulmonary tuberculosis in Rwanda. *BMC Infect Dis*. 2016;16(1):660.
- Lawn SD, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. *PLoS Med* 2011;8(7):e1001067-e.
- Bassett IV, et al. Intensive Tuberculosis Screening for HIV-Infected Patients Starting Antiretroviral Therapy in Durban, South Africa. *Clin Infect Dis*. 2010;51(7):823–829.
- Getahun H, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. *Lancet*. 2007;369(9578):2042–2049.
- Diedrich CR, O'Hern J, Wilkinson RJ. HIV-1 and the *Mycobacterium tuberculosis* granuloma: a systematic review and meta-analysis. *Tuberculosis (Edinb)*. 2016;98:62–76.
- Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. *J Infect Dis*. 2011;204(Suppl 4):S1159–S1167.
- Carriquiry G, et al. A diagnostic accuracy study of Xpert[®] MTB/RIF in HIV-positive patients with high clinical suspicion of pulmonary tuberculosis in Lima, Peru. *PLoS One*. 2012;7(9):e44626.
- Scott LE, et al. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. *PLoS Med*. 2011;8(7):e1001061.
- Boehme CC, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. *Lancet*. 2011;377(9776):1495–1505.
- Boehme CC, et al. Rapid molecular detection of tuberculosis and rifampin resistance. *N Engl J Med*. 2010;363(11):1005–1015.
- Seifert M, et al. Age and sex distribution of *Mycobacterium tuberculosis* infection and rifampicin resistance in Myanmar as detected by Xpert MTB/RIF. *BMC Infect Dis*. 2021;21(1):781.
- Horne DJ, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults. *Cochrane Database Syst Rev*. 2019;(6):33.
- World Health Organization. WHO guidelines approved by the guidelines review committee. automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children: policy update. Geneva, Switzerland: WHO, 2013.
- Elliott AM, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. *J Trop Med Hyg*. 1993;96(1):1–11.
- HIVinfo.NIH.gov. HIV and tuberculosis (TB). Rockville, MD, USA: aidsinfo.nih.gov, 2020. <https://aidsinfo.nih.gov/understanding-hiv-aids/fact-sheets/26/90/hiv-and-tuberculosis-tb-#:~:text=healthy%20immune%20systems.,HIV%20weakens%20the%20immune%20system%20C%20increasing%20the%20risk%20of%20TB,than%20in%20people%20without%20HIV>.
- Maynard-Smith L, et al. Diagnostic accuracy of the Xpert MTB/RIF assay for extrapulmonary and pulmonary tuberculosis when testing non-respiratory samples: a systematic review. *BMC Infect Dis*. 2014;14(1):709.
- Lyu M, et al. Which sample type is better for Xpert MTB/RIF to diagnose adult and pediatric pulmonary tuberculosis? *Biosci Rep*. 2020;40(8):BSR20200308.
- Van Deun A, et al. Sputum smear microscopy in the Xpert[®] MTB/RIF era. *Int J Tuberc Lung Dis*. 2019;23(1):12–18.
- Cox HS, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial. *PLoS Med*. 2014;11(11):e1001760.
- Sachdeva KS, et al. Use of Xpert MTB/RIF in decentralized public health settings and its effect on pulmonary TB and DR-TB case finding in India. *PLoS One*. 2015;10(5):e0126065.
- Adelman M, et al. Intensified tuberculosis case finding among HIV-infected persons using a WHO symptom screen and Xpert[®] MTB/RIF. *Int J Tuberc Lung Dis*. 2015;19(10):1197–1203.
- Hanrahan CF, et al. Implementation of Xpert MTB/RIF in Uganda: missed opportunities to improve diagnosis of tuberculosis. *Open Forum Infect Dis* 2016;3(2):3–6.
- Osei Sekyere J, et al. A comparative evaluation of the new Genexpert MTB/RIF Ultra and other rapid diagnostic assays for detecting tuberculosis in pulmonary and extra pulmonary specimens. *Sci Rep* 2019;9(1):16587.

R É S U M É

CONTEXTE : Xpert® MTB/RIF, un test de diagnostic moléculaire rapide de la TB, permet de détecter *Mycobacterium tuberculosis* et la résistance à la rifampicine directement à partir d'échantillons d'expectorations cliniques en <2 h avec une sensibilité et une spécificité élevées. La valeur diagnostique ajoutée d'Xpert par rapport à la microscopie à frottis au niveau national au Myanmar n'a pas été rapportée auparavant.

MÉTHODES : Nous avons évalué 339 358 enregistrements Xpert et démographiques saisis de janvier 2015 à décembre 2018 dans le cadre du projet d'utilisation et de connectivité des données du programme national de lutte contre la TB du Myanmar afin d'examiner le rendement diagnostique supplémentaire d'Xpert par rapport au frottis pour la détection de *M. tuberculosis* pour le diagnostic de la TB

au Myanmar, en mettant l'accent sur les personnes vivant avec le VIH (PLVIH) et le type d'échantillon.

RÉSULTATS : L'utilisation d'Xpert a augmenté de 40% la détection des cas de TB par rapport aux résultats de la microscopie à frottis. Chez les PLVIH, l'utilisation d'Xpert a augmenté la détection des cas de TB de presque 100% par rapport aux résultats de l'examen microscopique des frottis.

CONCLUSION : Le test Xpert a permis d'identifier plus de patients atteints de TB que la microscopie à frottis seule, en particulier dans les cohortes comportant une proportion importante de PLVIH. L'utilisation d'Xpert comme outil de dépistage dans les pays à forte charge de TB pourrait conduire à une augmentation significative du diagnostic de la TB au niveau régional et national.